124 related articles for article (PubMed ID: 7194923)
1. The management of advanced bladder carcinoma.
Kedia KR; Gibbons C; Persky L
J Urol; 1981 May; 125(5):655-8. PubMed ID: 7194923
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
Kotake T; Usami M; Miki T; Kuroda M; Obata K; Osafune M; Fujioka H; Takasugi Y
Cancer Chemother Pharmacol; 1983; 11 Suppl():S38-42. PubMed ID: 6685580
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study.
Mulder JH; Fossa SD; De Pauw M; Van Oosterom AT
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):111-2. PubMed ID: 7200890
[No Abstract] [Full Text] [Related]
4. Postoperative systemic adjuvant chemotherapy for bladder cancer.
Kiyohara H; Kuroda M; Saiki S; Miki T; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1987; 20 Suppl():S34-8. PubMed ID: 3664942
[TBL] [Abstract][Full Text] [Related]
5. A study of cyclophosphamide, adriamycin, cis-platinum, and methotrexate in advanced transitional cell carcinoma of the urinary tract.
Citrin DL; Hogan TF; Davis TE
Cancer; 1983 Jan; 51(1):1-4. PubMed ID: 6681590
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
Maru A; Akaza H; Isaka S; Koiso K; Kotake T; Machida T; Matsumura Y; Nakagami Y; Niijima T; Obata K
Cancer Chemother Pharmacol; 1987; 20 Suppl():S44-8. PubMed ID: 3311445
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
Campbell M; Baker LH; Opipari M; Al-Sarraf M
Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.
Logothetis CJ; Samuels ML; Ogden S; Dexeus FH; Swanson D; Johnson DE; von Eschenbach A
J Urol; 1985 Sep; 134(3):460-4. PubMed ID: 2993671
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
Sulkes A; Fuks Z
Cancer Treat Rep; 1983 Feb; 67(2):200-1. PubMed ID: 6681734
[No Abstract] [Full Text] [Related]
10. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for metastatic transitional carcinoma of the urinary tract. A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure.
Tannock IF; Gospodarowicz M; Evans WK
Cancer; 1983 Jan; 51(2):216-9. PubMed ID: 6681591
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of metastatic urothelial carcinoma].
Kihara K; Sakuramoto T; Washizuka M; Kawai T; Ogawa M
Gan To Kagaku Ryoho; 1982 Nov; 9(11):2046-7. PubMed ID: 6892194
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience.
Logothetis CJ; Dexeus FH; Chong C; Sella A; Ayala AG; Ro JY; Pilat S
J Urol; 1989 Jan; 141(1):33-7. PubMed ID: 2908950
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant treatment of stages T2 to T4 bladder cancer with cis-platinum, cyclophosphamide and doxorubicin.
McCullough DL; Cooper RM; Yeaman LD; Loomer L; Woodruff RD; Boyce WH; Harrison LH; Assimos DG; Lynch DF
J Urol; 1989 Apr; 141(4):849-52. PubMed ID: 2926878
[TBL] [Abstract][Full Text] [Related]
15. The effect of platinum analogues and combination chemotherapy on murine bladder cancer.
Soloway MS; Cox CE
Trans Am Assoc Genitourin Surg; 1979; 71():8-13. PubMed ID: 545820
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
17. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial.
Troner M; Birch R; Omura GA; Williams S
J Urol; 1987 Apr; 137(4):660-2. PubMed ID: 3550148
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy].
Uekado Y; Ogawa T; Yoshida T; Yamamoto S; Hirano A; Watanabe T; Shinka T; Ohkawa T
Hinyokika Kiyo; 1985 Aug; 31(8):1365-70. PubMed ID: 3841260
[TBL] [Abstract][Full Text] [Related]
19. [Polychemotherapy treatment with cisplatin, adriamycin, 5-fluorouracil (FAP) and cisplatin, adriamycin and cyclophosphamide (CISCA) in advanced transitional carcinoma of the bladder].
Sánchez Romero JA; Ramírez Ruiz F; Romero Fernández L; Pastor Gaitán P; Murillo Capitán E
Actas Urol Esp; 1989; 13(4):240-2. PubMed ID: 2678934
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
